Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
idiopathic pulmonary fibrosis
Fierce Biotech
Avalyn aims for $182M IPO to fund ph. 3 trials of lung drugs
Avalyn hopes to rake in $181.8 million, which the biotech will use to take inhaled versions of approved respiratory drugs into late-stage studies.
James Waldron
Apr 24, 2026 7:08am
Fierce Biotech
Avalyn plans IPO to fund ph. 3 trials of inhaled lung drugs
Apr 9, 2026 4:13am
United's Tyvaso backs up case for IPF expansion with ph. 3 win
Mar 30, 2026 3:06pm
Boehringer touts promising launches of Hernexeos, Jascayd
Mar 25, 2026 10:57am
BI's Jascayd quickly expands lung disease reach with new FDA nod
Dec 22, 2025 12:02pm
Boehringer breaks IPF treatment drought with new FDA approval
Oct 8, 2025 8:56am
Fierce Biotech
Fierce Biotech
Fierce Biotech
Fierce Biotech
